French biotech gets funding for universal flu and coronavirus vaccines 09-Jul-2020 By Ben Hargreaves Osivax receives public funding to apply its vaccine technology to protect against COVID-19 and future coronavirus strains.
Emergent signs $480m, five-year vaccine deal with J&J 07-Jul-2020 By Ben Hargreaves Emergent will provide contract development and manufacturing services for J&J’s potential COVID-19 vaccine.
J&J receives EU approval for Ebola vaccine 06-Jul-2020 By Ben Hargreaves The company becomes the second to receive approval, behind Merck, for its Ebola vaccine.
Takeda expands in gene therapy with $900m R&D deal 02-Jul-2020 By Ben Hargreaves Takeda signs R&D agreement with Carmine for the development of two non-viral gene therapies.
FDA says COVID-19 vaccine must be effective in half of recipients 01-Jul-2020 By Ben Hargreaves US FDA demands that vaccine must prevent or decrease severity in at least 50% of people receiving doses.
BioNTech receives $250m investment amid vaccine development 30-Jun-2020 By Staff Reporter June sees BioNTech secure hundreds of millions in investment to progress pipeline, including mRNA COVID-19 vaccine.
CSL Behring in $450m spend on hemophilia gene therapy 30-Jun-2020 By Ben Hargreaves The company buys the global rights to a gene therapy currently going through Phase III trials.
Gilead continues small deal spree 23-Jun-2020 By Ben Hargreaves Gilead buys a stake in Pionyr and holds the option to acquire the biotech outright.
Sanofi ties up $2.3bn Translate Bio agreement 23-Jun-2020 By Ben Hargreaves The partners extend an existing collaboration to develop mRNA vaccines against infectious diseases.
Biotech launches with $300m and ‘high precision’ cell therapies 23-Jun-2020 By Ben Hargreaves Orca Bio emerges with a manufacturing platform that it claims produces cell therapies with an ‘unprecedented turnaround time’.
Europe working to secure supply of J&J vaccine 22-Jun-2020 By Ben Hargreaves European Commission is working to guarantee access to J&J’s vaccine, as it bulks up vaccine supply, reports suggest.
Kite able to manufacture Yescarta in Europe after approval 16-Jun-2020 By Ben Hargreaves The cell therapy can now be produced for 4,000 patients per year in Europe.
AbbVie enters $3.8bn deal with Genmab 11-Jun-2020 By Ben Hargreaves The two companies will collaborate on Genmab’s lead bispecific antibody treatment and develop further candidates.
SUSupport expands to bring in Indian partner 10-Jun-2020 By Ben Hargreaves The Austrian startup provides its single-use equipment to PharmNXT in India.
AGC Biologics acquires commercial-scale facility from AstraZeneca 09-Jun-2020 By Ben Hargreaves The Colorado site currently possesses two 20,000L bioreactors, with the potential to add four more.
